Lecanemab winner in two categories at The Scrip Awards 2023
Stockholm, November 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry. The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates lecanemab as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive